Clinical trial
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With…
NCT00372996 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00372996 |
|---|---|
| Title | Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer |
| Official title | A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | CP-751, 871, exemestane, Fulvestrant |
| Enrollment | 219 |
| Start date | Feb 1, 2007 |
| Primary completion | Sep 1, 2012 |
| Completion | Jun 1, 2014 |
| First posted | Sep 7, 2006 |
| Last update posted | Oct 28, 2015 |
| Countries | Argentina, Belgium, Brazil, Canada, Italy, Netherlands, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: